* Newstin.co.uk is for sale! * After achieving our strategic milestone, we are offering for sale: Newstin.co.uk and all 14 related domains featuring 1 million unique visitors per month + continuously updated news database of 37 million articles in 12 world languages from 166,000 global and weighted sources + 2.1 billion metadata * To seize this unique chance, contact invest@newstin.com. * Newstin.co.uk is for sale! *

YM BioSciences

genengnews.com: Genetic Engineering genengnews.com

Final Call to Register for BioPartnering Europe (BPE)

euroinvestor.co.uk
02-Oct-2008 5 related
        

There are now just ten days to go until this year’s BioPartnering Europe which will be held on 12th-14th October, 2008 at the Queen Elizabeth Conference Centre in London, UK. Limited complimentary access to MedTRACK via...

add comment

YM Bio says Japanese, Korean nimotuzumab licencees begin enrolment for trial

finanznachrichten.de
01-Oct-2008
        

LONDON (Thomson Financial) - YM BioSciences Inc. said two of its licensees for nimotuzumab, Daiichi Sankyo Co. Ltd. and Korea-based Kuhnil Pharmaceutical Co., have commenced enrolment in an 80-patient Phase II trial....

add comment

Celator Pharmaceuticals appoints new CEO

pharmaceutical-business-review.com
01-Oct-2008
        

US based Celator Pharmaceuticals has appointed Scott Jackson as the company's new CEO. Mr Jackson succeeds Andrew Janoff. Celator Pharmaceuticals appoints new CEO Celator reports positive results from Phase II colorectal cancer...

add comment
                   

The Canadian Press Business News Budget for Friday, Sept. 19, 2008

tmcnet.com
20-Sep-2008
        

Via Acquire Media NewsEdge) BUSINESS EDITORS: Here are Canadian Press Business budget lines as of 9 p.m. ET. In addition to the following, a story slugged BC-Market-Mayhem, 1st Writethru has moved General (G) and Business...

add comment

YM BioSciences reports loss of $14.9 million in latest financial year

tmcnet.com
20-Sep-2008
        

Via Acquire Media NewsEdge) MISSISSAUGA, Ont. _ YM BioSciences Inc. (TSX:YM) said Friday it lost $14.9 million in its most recent financial year as the company continued its drug development work. The Toronto-based company...

add comment

Zosano Pharma hires CEO

pharmiweb.co.uk
08-Sep-2008 2 related
        

has appointed Gail Schulze as the company’s chair and CEO, Zosano said Monday. Schulze is charged with advancing the company’s osteoporosis treatment, a transdermal patch that delivers parathyroid hormone, the company...

add comment

YM BioSciences to present at the Canaccord Adams` 28th Global Growth Conference

pressebox.de
12-Aug-2008 29 related
        

12.08.2008 - 09:04 Uhr - YM BioSciences Inc. (AMEX:YMI, TSX:YM, AIM:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that Mr. David Allan,...

add comment

Ym Biosciences Reports Phase II Data For Nimotuzumab in Metastatic Colorectal Cancer

pressebox.de
05-Aug-2008 10 related
        

05.08.2008 - 12:01 Uhr - YM BioSciences Inc. (AMEX: YMI, TSX: YM, AIM: YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced preliminary results...

add comment
                   

YM Biosciences Presents Data Comparing Mechanism of Action for EGFR Antibody, Nimotuzumab to...

drugs.com
24-Jul-2008
        

Data Describes Nimotuzumab's Unique Binding Properties Resulting In Superior Side-Effect Profile Compared To Other EGFR-Targeting Drugs - MISSISSAUGA, ON, July 21 - YM BioSciences Inc. (AMEX: YMI, TSX: YM, AIM: YMBA), an...

add comment

YM BioSciences says data on lead drug shows superior side-effect profile

finanznachrichten.de
22-Jul-2008 3 related
        

LONDON (Thomson Financial) - YM BioSciences Inc, an AIM-listed cancer specialist, is presenting data on its lead drug, nimotuzumab, which it says shows how it has better side effects than rivals. Chief executive David Allan...

add comment
1 2 3 4 next »